MedTrace Logo

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

NCT03480776 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2026-01-14

No results posted yet for this study

Summary

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.

Conditions

  • Ovarian Cancer Prevention

Interventions

DRUG

Acetylsalicylic acid

81 mg PO daily or 325 mg PO daily

OTHER

Placebo

One tablet PO daily

Sponsors & Collaborators

  • Apotex Inc.

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Amit Oza · Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada

  • Stephanie Lheureux · Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-24
Primary Completion
2026-06-30
Completion
2026-09-15

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480776 on ClinicalTrials.gov